Mangoceuticals, Inc. Common Stock (MGRX) - Total Liabilities
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has total liabilities worth $1.65 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is Mangoceuticals, Inc. Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
Mangoceuticals, Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Mangoceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Mangoceuticals, Inc. Common Stock's balance sheet.
Mangoceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taranis Resources Inc
V:TRO
|
Canada | CA$1.07 Million |
|
Osmosun SA
PA:ALWTR
|
France | €2.84 Million |
|
Federal International Holdings Bhd
KLSE:8605
|
Malaysia | RM79.09 Million |
|
Express Transindo Utama Tbk
JK:TAXI
|
Indonesia | Rp3.65 Billion |
|
Sharc International Systems
F:IWIA
|
Germany | €4.86 Million |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $10.42 Million |
|
Kesla Oyj A
HE:KELAS
|
Finland | €19.34 Million |
|
Asmallworld AG
SW:ASWN
|
Switzerland | CHF7.49 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Mangoceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mangoceuticals, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mangoceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Mangoceuticals, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $890.57K | -37.52% |
| 2024-12-31 | $1.43 Million | +416.40% |
| 2023-12-31 | $276.04K | -29.09% |
| 2022-12-31 | $389.26K | +891.23% |
| 2021-12-31 | $39.27K | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more